Both in Pharmaceuticals
Cue Biopharma vs Pyxis Oncology
Over the past year CUE returned −3.1% and PYXS returned −57.0%; their daily moves had a correlation of -0.03.
CUE −3.1% PYXS −57.0%Growth of $1, one year, split-adjusted
| Metric | CUE | PYXS |
|---|---|---|
| Price | $20.86 | $1.64 |
| Market cap | $151.5M | $136.8M |
| Today | +7.42% | −2.96% |
| 1 month | −14.4% | −26.8% |
| 6 months | −40.3% | −10.4% |
| Year to date | +127.7% | +42.6% |
| 1 year | −9.4% | −53.9% |
| Revenue growth (YoY) | +166.7% | −100.0% |
| Gross margin | 100.0% | — |
| Net margin | −1943.2% | — |
| P/E (TTM) | — | — |
| Price / sales | 4.0× | 12.4× |
| Net cash | $16.4M | $33.0M |
| Dividend yield | — | — |
| Volatility (60d) | 138.5% | 112.4% |
| Short % of float | 12.2% | 7.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).